TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02416752
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
Study: NCT01174511
Drug: A -1 Cool Cream,Vaselin ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
Study: NCT00890253
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
Study: NCT00918047
Drug: SPN-804O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Label study
Study: NCT00722800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily for 24 weeks
Study: NCT00169533
Drug: GW572016 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib either at 750, 1000, 1250 or 1500 mgs
Study: NCT03909646
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
Study: NCT01516151
Drug: Lipid Lowering Medication
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be treated as per the Standard of care.
Study: NCT03592693
Drug: Combined Vitamin C and Stress-Dose Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
Study: NCT04180150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a treatment which is designed to have no therapeutic value.
Study: NCT02470026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single control treatment
Study: NCT00282178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00931879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Study: NCT00282412
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Causes prevention of cell division by forming adducts with DNA
Study: NCT00282412
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized monoclonal antibody against CD52 antigen
Study: NCT02221024
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00928837
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-steroidal anti-inflammatory drug
Study: NCT00820352
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice a day for 12 weeks
Study: NCT00734474
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734474
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00734474
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00785928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Study: NCT03325296
Drug: LEO 124249
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment containing LEO 124249
Study: NCT02470039
Drug: insulin 338 (GIPET I)
Normalized name: insulin isophane, human Injectable Suspension [Humulin I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
Study: NCT02470039
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily
Study: NCT03294538
Drug: Generic Estradiol Vaginal Cream USP, 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cream, generic formulation of the brand product.
Study: NCT03294538
Drug: Estrace® Vaginal Cream USP, 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cream, brand product.
Study: NCT03329118
Drug: SHR3824, Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
Study: NCT00493623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. single dose
Study: NCT00493623
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg i.v. single dose
Study: NCT00534625
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of placebo
Study: NCT00235469
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03286738
Drug: FOLFIRI, target agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab
Study: NCT00689780
Drug: AZD1940
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution Multiple ascending dose given orally once daily at day 1-12
Study: NCT06558097
Drug: XXB750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Study: NCT00449072
Drug: TAA-AQ, Nasacort® AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
Study: NCT00449072
Drug: Claritin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
Study: NCT00792948
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00792948
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00730522
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, bid, 12 weeks
Study: NCT02302573
Drug: contast-enhanced ultrasound with sonovue
Approvals — FDA: no, EMA: no, PMDA: no
Description: contast-enhanced ultrasound with sonovue
Study: NCT02410525
Drug: [11C]PF-06427878
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
Study: NCT02410525
Drug: PF-06427878 10 mg
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
Study: NCT04319484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 months after liver transplantation, participants are given Placebo with an initial dose of 8 mg (body weight \< 60 kg) or 12 mg orally once a day. The initial dose was 8 mg (body weight \< 60 kg) or 12 mg orally once a day.
Study: NCT00792948
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00792948
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT04261036
Drug: Ascorbic Acid 1000 mg
Normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
Study: NCT01645800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo capsule: Three times daily for 52 weeks.
Study: NCT02322346
Drug: Group LL
Normalized name: CELECOXIB N-DES(BENZENESULFONAMIDE) 200 mg ORAL CAPSULE [Truemed Group LLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study: NCT01557647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation solution
Study: NCT02322346
Drug: Group HL
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study: NCT04337268
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion for 60 min.
Study: NCT00075218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study: NCT00075218
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study: NCT03517449
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
Study: NCT05840640
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Study: NCT01627873
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
Study: NCT01627873
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
Study: NCT01388595
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
Study: NCT01620554
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per week during 2 weeks
Study: NCT01620554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per week during 2 weeks
Study: NCT05170841
Drug: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one single tablet to be taken every 8 hours
Study: NCT05170841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
Study: NCT01784757
Drug: ODM-201 capsule formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation of ODM-201
Study: NCT02760797
Drug: RO7009789
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7009789 will be administered IV every 3 weeks (every cycle).
Study: NCT01386346
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
Study: NCT02219633
Drug: LEO 39652 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied for 21 days
Study: NCT03970096
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03970096
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03806790
Drug: LEO 90100 foam
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
Study: NCT02352337
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
Study: NCT02352337
Drug: LV5FU2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion: Folinic Acid,5FU Bolus,5FU continue
Study: NCT02352337
Drug: FOLFIRI.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion :Irinotecan,Acide folinique ,5FU continue
Study: NCT01908127
Drug: injection of local anesthesia solution
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
Study: NCT03806790
Drug: Dovobet® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
Study: NCT01140074
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
Study: NCT00100165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth twice a day for 4 weeks
Study: NCT00409435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule per day for 3 days
Study: NCT03376594
Drug: Benjakul Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
Study: NCT00427492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02204371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
Study: NCT03643744
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
Study: NCT03643744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 placebo capsules taken 1 in the morning and 1 in the evening.
Study: NCT01720056
Drug: Kenalog 10
Normalized name: Kenalog 10 MG/ML Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02866175
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
Study: NCT03758365
Drug: MC2-01 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study: NCT03758365
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Study: NCT03943251
Drug: HEC113995PA•H2O tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
Study: NCT03943251
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
Study: NCT04669665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: NCT00843531
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day PO (oral)
Study: NCT02182102
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04665076
Drug: Cyclophosphamide,Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Cyclophosphamide,Fludarabine
Study: NCT00992069
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg in the morning
Study: NCT02737306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in parenteral solution.
Study: NCT01474278
Drug: RO5028442
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00901407
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 1-2 tablets bid; 10 weeks
Study: NCT02736760
Drug: Daylight photodynamic therapy using Methylaminolevulinate (MAL)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months.
Study: NCT00007878
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00007878
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01497483
Drug: Pravastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg with placebo.
Study: NCT03372317
Drug: 18F-MK-6240
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Study: NCT02315898
Drug: Treatment-inhaled tPA
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
Study: NCT04043845
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Study: NCT00343980
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study: NCT04355468
Drug: Opioid Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
Study: NCT03719586
Drug: MAb114
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Study: NCT01784042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01948505
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01948505
Drug: Placebo for IV acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02476526
Drug: Acetylcysteine Inhalation
Normalized name: acetylcysteine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)